Notice of Results

Eco Animal Health Group PLC

13 July 2026

 

13 July 2026

ECO Animal Health Group plc

("ECO" or the "Company")

Notice of Results

Analyst briefing and investor presentation

ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that it will issue its audited results for the year ended 31 March 2026 on 15 July 2026.

David Hallas, CEO, and Christopher Wilks, CFO, will host an in-person briefing for equity research analysts at 09:00 BST on 15 July 2026. There will be a dial-in option for those analysts unable to attend in person.

For further information about the analyst presentation, please contact [e-mail].

In addition, David Hallas and Christopher Wilks will conduct a live online presentation of the results at 09:00 BST on 16 July 2026.  This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at its conclusion.

To register for the event, please click here.

A recording will be available shortly after the event on Equity Development's website here.

-Ends-

Contacts

ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)	020 8447 8899
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson	020 3709 5700
Singer Capital Markets (Nominated Adviser & Joint Broker) Jen Boorer Jalini Kalaravy Samed Ethemi	020 7496 3000
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden	020 3100 2000
Equity Development Hannah Crowe Matt Evans	020 7065 2692

About ECO Animal Health

ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.

The Group's proprietary lead product, Aivlosin® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.

ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO's pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in June 2026.

Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.

View the Group's website or LinkedIn page for further information.

 

END